Drug Trial Radar · NCT06632977
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
474
Planned (sponsor's estimate)
Start
Feb 6, 2025
Primary completion
Apr 11, 2030
Study completion Oct 11, 2034
Sponsor
- Lead sponsor
- Alliance for Clinical Trials in OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Oct 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) abnormalities or mutations in their cancer. Valemetostat tosylate is in a class of medications called EZH1/EZH2 inhibitors. It blocks proteins called EZH1 and EZH2, which may help slow or stop the spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Cabazitaxel injection is in a class of medications called microtubule inhibitors. It works by slowing or stopping the growth of tumor cells. Abiraterone acetate blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of tumor cells that need androgens to grow. It is a type of anti-androgen. Enzalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Lutetium Lu 177 vipivotide tetraxetan is in a class of medications called radiopharmaceuticals. It works by targeting and delivering radiation directly to tumor cells which damages and kills these cells. Assigning patients to targeted treatment based on genetic testing may help shrink or slow the cancer from growing
Conditions
- Castration-Resistant Prostate Carcinoma
- Stage IVB Prostate Cancer AJCC v8
Interventions
Genetic testingOther
undergo genetic testing
Valemetostat TosylateDrug
Given PO
Magnetic Resonance ImagingProcedure
undergo Magnetic Resonance Imaging
Computed TomographyProcedure
undergo Computed Tomography
Bone scanProcedure
undergo Bone scan
FDG-Positron Emission TomographyProcedure
Undergo FDG PET
PSMA PET ScanProcedure
Undergo PSMA PET
Biospecimen CollectionProcedure
undergo blood collection
CarboplatinDrug
Given IV
CabazitaxelDrug
Given IV
Abiraterone AcetateDrug
Given PO
EnzalutamideDrug
Given PO
Lutetium Lu 177 Vipivotide TetraxetanDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective ResponseTime frame: Within 6 months from the start of treatment
Locations
108 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
Enloe Medical Center
Chico, California · Recruiting
UC San Diego Health System - Encinitas
Encinitas, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Active not recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Active not recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
UC San Diego Medical Center - Hillcrest
San Diego, California · Recruiting
UCHealth Memorial Hospital Central
Colorado Springs, Colorado · Recruiting
Memorial Hospital North
Colorado Springs, Colorado · Recruiting
Poudre Valley Hospital
Fort Collins, Colorado · Recruiting
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado · Recruiting
UCHealth Greeley Hospital
Greeley, Colorado · Recruiting
Medical Center of the Rockies
Loveland, Colorado · Recruiting
Stamford Hospital/Bennett Cancer Center
Stamford, Connecticut · Recruiting
Beebe South Coastal Health Campus
Millville, Delaware · Recruiting
Helen F Graham Cancer Center
Newark, Delaware · Recruiting
Medical Oncology Hematology Consultants PA
Newark, Delaware · Recruiting
Beebe Health Campus
Rehoboth Beach, Delaware · Recruiting
Jupiter Medical Center
Jupiter, Florida · Recruiting
Tripler Army Medical Center
Honolulu, Hawaii · Recruiting
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Suspended
Illinois CancerCare-Bloomington
Bloomington, Illinois · Recruiting
Illinois CancerCare-Canton
Canton, Illinois · Recruiting
Carle at The Riverfront
Danville, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Recruiting
Illinois CancerCare-Eureka
Eureka, Illinois · Recruiting
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois · Recruiting
Cancer Care Center of O'Fallon
O'Fallon, Illinois · Recruiting
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois · Recruiting
Illinois CancerCare-Pekin
Pekin, Illinois · Recruiting
Illinois CancerCare-Peoria
Peoria, Illinois · Recruiting
Illinois CancerCare-Peru
Peru, Illinois · Recruiting
Memorial Hospital East
Shiloh, Illinois · Recruiting
Carle Cancer Center
Urbana, Illinois · Recruiting
Illinois CancerCare - Washington
Washington, Illinois · Recruiting
McFarland Clinic - Ames
Ames, Iowa · Recruiting
University of Iowa Healthcare Cancer Services Quad Cities
Bettendorf, Iowa · Recruiting
Showing 40 of 108 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.